Find Academic Supervisors

• Pediatric Oncology
• Neuroblastoma Research
• Immunotherapy
• +3 more

Shahab Asgharzadeh is a Professor of Pediatrics and Pathology at the Keck School of Medicine, University of Southern California. His research focuses on pediatric oncology, particularly neuroblastoma, with emphasis on tumor microenvironment interactions, immunotherapy strategies, and molecular mechanisms of cancer progression. He leads studies on CAR-T cell therapies, chemoresistance mechanisms, and biomarker discovery for high-risk neuroblastoma patients. His work integrates stem cell biology, epigenetics, and genomic analysis to uncover therapeutic targets. Notable contributions include identifying AF1q as a neuroblastoma biomarker and elucidating ALK-driven tumor pathways. He collaborates with the Children’s Oncology Group (COG) on clinical trials evaluating novel therapeutics and risk stratification systems. Key research trends in his articles include: 1) Development of targeted immunotherapies to enhance specificity and reduce toxicity, 2) Molecular characterization of tumor heterogeneity and drug resistance, 3) Role of cytokine signaling (e.g., CCL2, TGF-β) in tumor progression and immune evasion. His studies frequently involve mouse models, patient-derived xenografts, and genomic profiling to bridge basic science and clinical applications. His clinical contributions include optimizing vitamin D regimens in stem cell transplantation and refining risk classification systems for neuroblastoma. He holds no explicitly stated awards but has authored over 300 peer-reviewed publications since 2004.

• Head and Neck Cancer
• Human Papillomavirus (HPV) Vaccination
• Otolaryngology
• +5 more

Niels Kokot, MD is a Clinical Professor in the Department of Otolaryngology-Head & Neck Surgery at the Keck School of Medicine of USC , University of Southern California. His clinical and research focus spans head and neck oncology, HPV vaccination dynamics, reconstructive surgery, and health disparities in cancer survivorship. Role: Clinical Professor, Otolaryngology-Head & Neck Surgery Affiliation: Keck School of Medicine of USC Email: kokot@usc.edu Research Interests include head and neck cancer, HPV-related pathogenesis, reconstructive microsurgery, psychosocial determinants of postoperative outcomes, and health equity. He investigates disparities in cancer diagnosis, treatment of minority populations, and the role of digital platforms in patient education. Recent Publications highlight trends in cost-effectiveness of surveillance imaging, free flap outcomes, and the intersection of social media with health communication. His work spans clinical trials, systematic reviews, and epidemiological studies. Collaborations involve multidisciplinary teams, including critical care, endocrinology, and medical oncology. His career bridges basic science (notably cytokine signaling in the 1990s) with contemporary clinical and health systems research.

• Breast Imaging
• Radiology
• Oncology
• +3 more

Dr. Pulin A. Sheth is a Clinical Professor of Radiology (Clinician Educator) at the Keck School of Medicine of the University of Southern California (USC). He serves as the Medical Director of Breast Imaging at the USC Norris Comprehensive Cancer Center and leads the Breast MRI program across multiple USC-affiliated hospitals. His career spans academic and clinical roles, with expertise in breast imaging, neoadjuvant chemotherapy monitoring, and breast cancer diagnosis. Dr. Sheth holds medical directorships in radiology and breast imaging at Keck Medicine of USC, contributing to both patient care and medical education. Education: MD from University of California, San Diego School of Medicine. Training: Diagnostic Radiology residency at Kaiser Permanente, Los Angeles; fellowship in women’s imaging at Emory University. His research focuses on advancing diagnostic accuracy in breast cancer through imaging technologies like MRI and ultrasound, particularly in evaluating treatment response to neoadjuvant chemotherapy. He also investigates breast density legislation impacts, occult lesion detection, and overdiagnosis concerns in benign lesions. Dr. Sheth’s work emphasizes improving clinical decision-making through modified BI-RADS scoring and optimizing imaging protocols. Publications highlight his contributions to understanding MRI’s role in treatment monitoring, comparative imaging modalities, and population-based outcomes. His clinical innovations, such as targeted intraoperative radiotherapy, aim to reduce treatment burden while maintaining efficacy. Dr. Sheth has held academic positions since 2001 and expanded breast imaging services across USC’s health systems, serving both academic and community populations. His leadership in breast MRI at LAC+USC Medical Center and Verdugo Hills Hospital establishes him as a key figure in Los Angeles’s breast cancer referral network.

• Oncology
• Urothelial Carcinoma
• Kidney Cancer
• +5 more

Dr. Varsha Tulpule is Clinical Assistant Professor in the Department of Medicine at the University of Southern California, specializing in genitourinary oncology. Her research focuses on molecular mechanisms of treatment resistance in kidney and bladder cancers, with emphasis on epigenetic alterations and liquid biopsy applications. Publications explore SETD2-deficient renal cancer vulnerabilities, albumin as a prognostic biomarker in tyrosine kinase inhibitor therapy, and clinical utility of circulating tumor cell analysis. Recent work establishes guidelines for upper tract urothelial carcinoma management and metastatic prostate cancer liquid biopsy integration. Collaborates with cancer genomics initiatives to identify novel therapeutic targets and develops diagnostic platforms for minimally invasive cancer monitoring.

Manoj JainView profile

Adjunct Professor

• HIV Epidemiology
• Healthcare Quality Improvement
• Infectious Diseases
• +3 more

Dr. Manoj Jain is an Adjunct Professor at Emory University's Rollins School of Public Health and a Clinical Associate Professor at the University of Tennessee, Memphis. He is an infectious disease consultant at Baptist Memorial Hospital and Methodist Hospitals in Memphis. Dr. Jain holds degrees from Boston University, including a Doctorate in Medicine and a Master of Public Health. His research focuses on HIV epidemiology, healthcare quality improvement, and the intersection of spirituality with medical practice. He has authored numerous books and scientific articles, including works on HIV management, healthcare ethics, and vegetarian cuisine. Education: Bachelors in Engineering, MD, MPH from Boston University Residencies: Boston City Hospital, Tufts University, Harvard School of Public Health Dr. Jain is a prolific writer with over 150 columns in outlets like the New York Times, Washington Post, and Times of India. His work addresses healthcare policy, medical ethics, and global health challenges. He has served as a World Bank consultant on HIV and frequently discusses topics like medical errors, patient safety, and cultural health practices. His interdisciplinary approach bridges clinical medicine, public health, and humanities. His articles explore diverse themes including mindfulness in medicine, childhood obesity interventions, and the ethical implications of terminal care. Dr. Jain advocates for compassionate healthcare delivery and the importance of physician-patient communication, emphasizing the role of humility and apology in medical practice.

• Neurology
• Medical Research
• Epidemiology
• +3 more

Simone Dijkland is a Researcher at the Neurology department of Erasmus MC, specializing in clinical decision-making models and evidence synthesis. Their work focuses on improving patient outcomes through predictive analytics in neurology and oncology, with notable contributions to aneurysm treatment protocols and mortality prediction in chronic diseases. Research interests include meta-analyses, systematic reviews, and developing prognostic models for conditions like traumatic brain injury and chronic obstructive pulmonary disease. Collaborations include the CENTER-TBI initiative for neurotrauma research. Recent publications (2022–2024) emphasize clinical prediction tools, comparative treatment analyses, and mortality risk assessment in major health conditions. Their work combines statistical rigor with translational clinical applications.

• Oncology
• Pharmacology
• Clinical Trials
• +2 more

Stefan Sleijfer is a Professor and Dean at Erasmus MC, Erasmus University Rotterdam, specializing in oncology and pharmacological research. His work focuses on translational cancer research, particularly in metastatic diseases and biomarker development. Research interests include: Targeted cancer therapies using circulating tumor DNA Characterization of tumor microenvironments Clinical trial methodology optimization Genomic drivers of metastasis Precision medicine approaches to solid tumors Recent publications demonstrate a strong focus on breast cancer and melanoma, exploring molecular diagnostics and novel therapeutic combinations. His work integrates genomic, transcriptomic, and clinical data to advance personalized cancer treatment strategies.

• Cancer Biology
• Non-coding RNA
• Breast Cancer Heterogeneity
• +2 more

Róża Przanowska is a Postdoctoral Research Fellow in Biomedical Engineering at the University of Virginia, specializing in non-coding RNAs in cancer and development. Her research focuses on breast cancer heterogeneity using novel organoid models and lncRNA functional studies. She collaborates with Dr. Kevin Janes and Dr. Shayna Showalter on translational projects supported by the National Cancer Institute and UVA Coulter Center grants. Education: PhD in Biochemistry and Molecular Genetics (UVA, 2021), MSc and BSc in Biotechnology from University of Warsaw, with international training at Max Planck Institute (2014) and a Fulbright Scholarship at UVA (2015). Research interests include lncRNA structure-function relationships, tumor heterogeneity modeling, and translational oncology. Her work bridges basic science and clinical applications through organoid-based patient-specific models. Key achievements include developing zero-passage organoids for breast cancer studies, leading to a 2024 Coulter Center award. Her research has been recognized with over 20 awards including the NCI F99/K00 fellowship (2020-2025) and multiple institutional awards for research and leadership. Grants include NIH K00CA253732 studying lncRNA heterogeneity in ER+ breast cancer, and Coulter funding for organoid-based clinical trial support (POWER II). She also contributed to the Hamlin Lecture Series and taught in the Biomedical Sciences Summer Prep program (2018-2020). Her lab focuses on cancer systems biology, with collaborations in tumor organoid development and molecular mechanisms of lncRNA-driven heterogeneity. Current efforts aim to translate organoid models into clinical decision tools for breast cancer therapies.

Gizeh Perez-TenorioView profile

Researcher

• Breast Cancer Research
• Molecular Oncology
• Hormonal Therapy
• +3 more

Gizeh Perez-Tenorio is a Docent and Principal Research Engineer at Linköping University, affiliated with the Department of Biomedical and Clinical Sciences (BKV) and the Division of Surgery, Orthopedics and Oncology. She also serves as a Project Manager at the Commissioned Education Office, fostering collaborations between healthcare regions and educational institutions. Her primary research focuses on molecular mechanisms underlying late recurrence of ER+ breast cancer, including PIK3CA mutations, tumor-infiltrating lymphocytes (TILs), and tumor dormancy. As an educational developer at Didacticum and board member of Swednet, she emphasizes lifelong learning in healthcare education. She supervises medical students and contributes to the international course ONL. Her work bridges oncology research with practical healthcare education, aiming to improve treatment strategies and patient outcomes in breast cancer.

Maheswari SenthilView profile

Professor

• Surgical Oncology
• Peritoneal Carcinomatosis
• Gastrointestinal Cancer
• +4 more

Maheswari Senthil is a Professor in the Division of Surgical Oncology at the UCI School of Medicine. She holds leadership roles including Chief of the Division of Surgical Oncology, Vice Chair of Surgical Research, and Medical Director of the UCI Center for Clinical Research. Her work focuses on peritoneal malignancies, colorectal cancer, and innovative therapies like cytoreductive surgery combined with HIPEC. She leads the Peritoneal Malignancy Program at the Chao Family Comprehensive Cancer Center. Research Interests: Her research emphasizes peritoneal carcinomatosis, gastrointestinal malignancies, and translational studies in surgical oncology. She explores biomarkers (e.g., exosomes) for early detection and treatment response prediction. Her work also addresses disparities in cancer care and palliative treatment utilization. Clinical Contributions: Dr. Senthil is a leader in advancing surgical techniques and multidisciplinary approaches for advanced cancers. She contributes to global initiatives to improve cancer surgery outcomes in resource-limited settings.

David WildView profile

Professor

• Statistical Bioinformatics
• Bayesian Computation
• Systems Biology
• +5 more

Prof. David Wild is a Professor in the Department of Statistics and Zeeman Institute at the University of Warwick. His research focuses on statistical bioinformatics, Bayesian computation, and systems biology, with applications in functional genomics, proteomics, and protein energetics. He has been funded by organizations including the UK BBSRC, EPSRC, EU, and the US NSF and NIH. His work includes developing state-space models for gene regulatory networks, nonparametric Bayesian methods for data fusion, and computational approaches to protein folding and energetics. Collaborations include Lorantis Ltd., Warwick School of Life Sciences, and the University of Birmingham. Recent projects involve inferring dynamic biological networks with time-varying topologies, improving computational efficiency via GPU methods, and advancing knowledge of protein energetics using Bayesian techniques. Future research aims to explore synthetic biology applications in protein design. Key funding sources include the BBSRC (SABR/SYSMO initiatives), EPSRC, EU, Leverhulme Trust, and NIH/NSF grants. His lab's work has led to advancements in understanding plant responses to pathogens and environmental stress, as well as T-cell activation dynamics.

Johan HartmanView profile

Professor

• Precision Pathology
• Breast Cancer Therapy
• Digital Image Analysis
• +4 more

Professor Johan Hartman is a leading academic and clinician at Karolinska Institutet, serving as a Professor and Senior Consultant in the Department of Oncology-Pathology. His primary role combines research leadership in precision pathology with clinical expertise in breast pathology at Karolinska University Hospital. Hartman leads a research group focused on personalized breast cancer therapy through advanced technologies like AI-driven histopathology analysis, molecular genomics, and patient-derived tumor models. Education & Qualifications: Doctoral Degree (2008), Karolinska Institutet Medical Degree (2008), Karolinska Institutet Docent (2015), Karolinska Institutet Research Focus: Hartman’s lab pioneers innovations in precision medicine, particularly in predicting treatment responses using digital pathology, AI, and genomic profiling. Key areas include tumor heterogeneity, AI tools for diagnostic accuracy, and translational research linking molecular profiles to clinical outcomes. His group has developed clinical-grade AI systems for breast cancer risk stratification and tumor characterization. Publications & Impact: With over 100 peer-reviewed articles in high-impact journals (e.g., Science, Nature Communications), Hartman’s work emphasizes breast cancer therapy prediction, immune profiling, and molecular diagnostics. Recent studies include AI-driven TIL analysis, spatial transcriptomics, and genomic heterogeneity in tumors. Awards & Recognition: 2023 Karolinska Institutet Innovation Award 2022 Athena Prize (Vetenskapsrådet) 2016 Clinical Investigator Award (Swedish Cancer Society) Grants & Collaborations: Leading projects funded by Radiumhemmets Forskningsfonder, Vinnova, and industry partnerships Co-founder of Stratipath, a KI spin-off advancing precision pathology tools Labs & Teams: Hartman’s group includes postdocs, PhD students, and clinical researchers. Key members focus on AI in pathology, tumor modeling, and translational oncology. The team collaborates internationally on initiatives like the International Immuno-Oncology Biomarker Working Group.

Johan LundinView profile

Professor

• Medical Technology
• Artificial Intelligence in Healthcare
• Global Health
• +3 more

Johan Lundin is a Professor of Medical Technology at the Department of Global Public Health, Karolinska Institutet, and Research Director at the Institute for Molecular Medicine Finland (FIMM), University of Helsinki. His research focuses on digital diagnostics and artificial intelligence (AI) for improving patient care, particularly in resource-limited settings. Key areas include image-based diagnostics for cancer, infectious diseases, and burn injuries, with an emphasis on point-of-care solutions. He holds a Docent title from the University of Helsinki (2003). Lundin leads the MoMic Project, supported by a 10M SEK grant from the Erling-Persson Family Foundation, which develops AI-driven mobile microscopy for diagnostics in collaboration with Kenyan partners. His work includes validation studies in Kenya on cervical cancer screening, helminth infection monitoring, and malaria treatment efficacy. Lundin’s research group has pioneered cloud-based platforms like the WebMicroscope and mobile microscopy tools. He collaborates internationally, including with Uppsala University and Kinondo Kwetu Hospital in Kenya, under the GlobeLife initiative. His scientific contributions span over 150 peer-reviewed articles in journals like PLOS Digital Health, Nature, and Lancet Public Health. Awards include the Erling-Persson Family Foundation Grant (2021-2024), recognizing his innovation in global health diagnostics. His future work aims to scale AI diagnostics to enhance equity in healthcare access through sustainable technologies.

Klaus-Martin SchulteView profile

Professor

• Indigenous Pharmacogenomics
• Space Medicine
• Cancer Biology
• +3 more

Prof. Klaus-Martin Schulte is the Professor & Chair of Transdisciplinary Health Research at the Australian National University (ANU) and holds an Honorary Reader position at King's College London. His clinical roles include Consultant Endocrine and General Surgeon at King’s College Hospital (part-time since 2014) and Lead Clinician in Endocrine Surgery. He has extensive experience in surgical oncology, endocrine disorders, and translational research. Education: MD from University of Duisburg-Essen (1990) Postgraduate training at Harvard Medical School, Baylor College of Medicine, and University of Paris PhD in molecular endocrinology (1990) FRACS (Fellow of the Royal Australasian College of Surgeons) and FRCS (Fellow of the Royal College of Surgeons of England) Research Interests: Focus on Indigenous Pharmacogenomics , Space Medicine , and Cancer Biology . His work includes developing surgical oncology protocols for endocrine cancers (e.g., parathyroid carcinoma, pheochromocytoma) and investigating space-related health challenges like microgravity effects on cardiovascular systems. Key Projects: iLAuNCH: Wearable health solutions for space medicine Pharmacogenomics pipeline for Indigenous health equity Software-defined radio for satellite communications Awards: von Langenbeck Award for surgical innovation (2002) Oberdisse Award for thyroid research (1998) Multiple Clinical Excellence Awards (2004–present) Grants & Funding: Principal investigator in 4 DFG-funded projects and multiple NHMRC-like grants. Current leadership roles in ANU’s Transdisciplinary Health Research division. Future Work: Expanding space medicine collaborations and advancing precision medicine for endocrine tumors.

Kelechi NjokuView profile

Academic

• Endometrial Cancer
• Biomarker Research
• Proteomics
• +6 more

Dr. Kelechi Njoku is an NIHR Clinical Lecturer in Cancer Diagnostics and Machine Learning at the University of Manchester, and an Academic Futures Scholar in Evidence-Based Health Care at the University of Oxford. He holds an honorary Clinical Oncology Specialist Registrar position at Christie NHS Foundation Trust. His research focuses on biomarker discovery for endometrial and ovarian cancers using proteomics and machine learning, with a particular emphasis on non-invasive diagnostic approaches. Education includes a PhD in Cancer Sciences (University of Manchester), a Master's in Public Health (Newcastle University), and a Post-graduate Certificate in Health Research (University of Leeds). He is a member of the Royal College of Physicians (MRCP) and has been awarded prestigious fellowships from Cancer Research UK and the Wellcome Trust. Research interests span biomarker development, proteomics, data science, and cancer epidemiology. Key achievements include the Edgar Gentilli Prize for cancer research and the Sir William Gilliatt Award for outstanding academic presentations. His work contributes to UN Sustainable Development Goals related to improving health equity and reducing cancer mortality. Recent publications explore urinary biomarkers, SWATH proteomic profiling, and machine learning-driven diagnostic tools. He collaborates internationally on projects like the DETECT study for endometrial cancer detection. Grants include support from the Eve Appeal and North West Cancer Research. Dr. Njoku leads projects on biomarker validation and clinical translation, with active lab involvement in proteomic analysis and computational biology. Future work aims to integrate AI into diagnostic workflows to improve cancer patient outcomes.